Market Momentum: X4 Pharmaceuticals Inc (XFOR) Registers a -2.76 Decrease, Closing at 0.55

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed the day trading at $0.55 down -2.76% from the previous closing price of $0.56. In other words, the price has decreased by -$2.76 from its previous closing price. On the day, 2.17 million shares were traded. XFOR stock price reached its highest trading level at $0.5788 during the session, while it also had its lowest trading level at $0.5369.

Ratios:

For a better understanding of XFOR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.71 and its Current Ratio is at 3.71. In the meantime, Its Debt-to-Equity ratio is 56.03 whereas as Long-Term Debt/Eq ratio is at 54.94.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.

On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Mostafa Adam S. sold 52,500 shares for $0.88 per share. The transaction valued at 46,347 led to the insider holds 0 shares of the business.

Ragan Paula sold 49,678 shares of XFOR for $43,856 on Mar 11 ’24. The President and CEO now owns 765,068 shares after completing the transaction at $0.88 per share. On Mar 11 ’24, another insider, DiBiase Mary, who serves as the Chief Operating Officer of the company, sold 15,409 shares for $0.88 each. As a result, the insider received 13,591 and left with 291,752 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 92181168 and an Enterprise Value of 69587048.

Stock Price History:

The Beta on a monthly basis for XFOR is 0.35, which has changed by -0.72821784 over the last 52 weeks, in comparison to a change of 0.26253593 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $2.06, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is -44.35%, while the 200-Day Moving Average is calculated to be -41.81%.

Shares Statistics:

Over the past 3-months, XFOR traded about 3.14M shares per day on average, while over the past 10 days, XFOR traded about 5063390 shares per day. A total of 167.43M shares are outstanding, with a floating share count of 117.37M. Insiders hold about 30.11% of the company’s shares, while institutions hold 39.63% stake in the company. Shares short for XFOR as of 1718323200 were 11920391 with a Short Ratio of 3.80, compared to 1715731200 on 12213183. Therefore, it implies a Short% of Shares Outstanding of 11920391 and a Short% of Float of 7.16.

Earnings Estimates

The stock of X4 Pharmaceuticals Inc (XFOR) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.34 and a low estimate of -$0.24, while EPS last year was -$0.33. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.17 and low estimates of -$0.19.

Analysts are recommending an EPS of between -$0.21 and -$0.8 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.47, with 7.0 analysts recommending between -$0.1 and -$0.7.

Revenue Estimates

For the next quarter, 6 analysts are estimating revenue of $1.72M. There is a high estimate of $3.45M for the next quarter, whereas the lowest estimate is $750k.

Based on 7 analysts’ estimates, the company’s revenue will be $48.08M in the next fiscal year. The high estimate is $140.7M and the low estimate is $9.32M.

Most Popular